Gene Therapy Guidances From US FDA Coming In About 6 Weeks, Gottlieb Says
Executive Summary
Potential accelerated approval endpoints will be addressed; FDA Commissioner expects gene therapy to become a 'backbone' treatment as antibodies are now.
You may also be interested in...
Gene Therapy Oversight To Be Streamlined By US FDA, NIH
Streamlining adverse event reports among reform ideas; NIH's Recombinant DNA Advisory Committee likely to drop review of more routine protocols.
Gene Therapies Need Long-Term Follow-Up Plan From Outset Or Risk Clinical Hold
Although a sponsor may conclude that a long-term follow-up protocol is not necessary for a gene therapy, FDA may have a different interpretation, and the agency won't let studies start if that's the case, draft gudiance states.
Gene Therapy 'Cassettes' Could Speed, Cheapen Manufacturing, Gottlieb Says
US FDA Commissioner teases endpoints, suggests accelerated approval plan and post-marketing considerations for gene therapies targeting hemophilia.